title: Connective tissue diseases: What does the death of Riquent hold for the future of SLE?
abstract: In clinical trials testing new treatments for systemic lupus erythematosus (SLE), the failure of the 15-year drug development program for riquent (abetimus sodium) is the latest in a string of disappointments for a disease that has seen no new drugs approved in over 50 years.
authors.forename: Joan T
authors.initials: JT
authors.lastname: Merrill
authors.forename: Jill P
authors.initials: JP
authors.lastname: Buyon
mesh_terms: D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D009841:Oligonucleotides / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D017211:Treatment Failure
chemical_list: D009841:Oligonucleotides; C094104:abetimus